Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hidradenitis Suppurativa: early-phase trial registry
29 of 53 indexed Hidradenitis Suppurativa trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 29 currently recruiting · #265 of 28,707 conditions by registered trial count
Hidradenitis Suppurativa: 53 US clinical trials tracked, 29 recruiting.
Hidradenitis Suppurativa is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 5 of these trials.
Enrollment posture brief
Registry condition hidradenitis-suppurativa
OPEN 29 | RECR 55% | LATE 14 | EARLY 24 | RANK #265 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage I Breast Cancer AJCC v8 (55% recruiting · 64 trials)
Hidradenitis Suppurativa lists 29 open slots (55% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hidradenitis Suppurativa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hidradenitis Suppurativa is recruiting above its size-band peers.
29 of 53 indexed trials (54.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hidradenitis Suppurativa trials is spread across many organizations.
Novartis Pharmaceuticals accounts for 5 of 53 trials (9.4%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Hidradenitis Suppurativa enrolment sits around 144 participants.
Median target enrolment is 144 among the 53 trials that report a genuine target (sentinel values excluded). 26 of those (49.1%) plan for fewer than 100 participants.
-
Hidradenitis Suppurativa research is mostly interventional.
45 interventional and 8 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 1 of 2
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
University of California, San Francisco
NCT04115566
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie
NCT05889182
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie
NCT06468228
Clinical and Biological Characteristics of Hidradenitis Suppurativa
University of California, San Francisco
NCT03967600
Myriad™ Augmented Soft Tissue Reconstruction Registry
Aroa Biosurgery Limited
NCT05243966
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Novartis Pharmaceuticals
NCT06840392
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Novartis Pharmaceuticals
NCT06799000
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Incyte Corporation
NCT06958211
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Incyte Corporation
NCT06959225
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Pfizer
NCT07228390
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Sanofi
NCT07170917
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
University of Alabama at Birmingham
NCT05507125
The Ohio State University Dermatology Biorepository
Ohio State University
NCT03146676
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Sanofi
NCT07225569
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Takeda
NCT07244263
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AbbVie
NCT06524635
Physical Activity in Hidradenitis Suppurativa (HS)
University of Miami
NCT06015438
Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin
Johns Hopkins University
NCT05066113
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL
NCT06921850
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
MoonLake Immunotherapeutics
NCT06768671
Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
Wayne State University
NCT04218422
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Milton S. Hershey Medical Center
NCT04414514
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Incyte Corporation
NCT07049575
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
NCT06888193
Botulinum Toxin Therapy in Hidradenitis Suppurativa
University of Massachusetts, Worcester
NCT05403710
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
University of Minnesota
NCT06058520
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
University of Alabama at Birmingham
NCT06326476
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
Tulane University
NCT07077902
Aviclear for Hidradenitis Suppurativa (HS)
University of Miami
NCT06801795
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Target PharmaSolutions
NCT03661866
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Novartis Pharmaceuticals
NCT04179175
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL
NCT04901195
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics
NCT06411899
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics
NCT06411379
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Eli Lilly and Company
NCT06046729
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics
NCT06603077
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Novartis Pharmaceuticals
NCT03827798
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Insmed Incorporated
NCT06685835
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
AbbVie
NCT05139602
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Merck Sharp & Dohme
NCT06956235
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
Sonoma Biotherapeutics
NCT06361836
Anifrolumab for Hidradenitis Suppurativa
University of North Carolina, Chapel Hill
NCT06374212
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Novartis Pharmaceuticals
NCT03713632
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB Biopharma SRL
NCT04242446
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
Sanofi
NCT05849922
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
Eli Lilly and Company
NCT04493502
Hidradenitis Suppurativa Mail Survey
Wake Forest University Health Sciences
NCT03572738
Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa
Henry Ford Health System
NCT00494351
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa
Florida Academic Dermatology Centers
NCT02695212
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
Henry Ford Health System
NCT01063270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 19 |
| Phase 3 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Hidradenitis Suppurativa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hidradenitis Suppurativa trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hidradenitis Suppurativa page
53 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Hidradenitis Suppurativa trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Hidradenitis Suppurativa trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hidradenitis Suppurativa condition card totals 53 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.